Roche announced that the European Commission approved the expansion of the Hemlibra European Union marketing authorization. The label will now include the routine prophylaxis of bleeding episodes in people with hemophilia A without factor VIII inhibitors, who have moderate disease with a severe bleeding phenotype. "We welcome the European Commission’s decision to approve Hemlibra also for people with moderate hemophilia A in the EU, since even moderate disease can produce bleeds that cause irreversible joint damage and impact quality of life," said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Development.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on RHHBY:
- [Ad hoc announcement pursuant to Art. 53 LR] Roche reports good results for 2022 despite decline in demand for COVID-19 products
- [Ad hoc announcement pursuant to Art. 53 LR] Changes in Roche’s Corporate Executive Committee
- European Commission approves label expansion of Roche’s Hemlibra to include people with moderate haemophilia A in the EU
- Roche price target lowered to CHF 350 from CHF 380 at Berenberg
- Jana Care, Roche collaborate to develop, distribute blood testing platform